van Trommel Nienke E, Sweep Fred C G J, Schijf Charles P T, Massuger Leon F A G, Thomas Chris M G
Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Eur J Endocrinol. 2005 Oct;153(4):565-75. doi: 10.1530/eje.1.01997.
Human chorionic gonadotropin (hCG) is widely used in the management of hydatidiform mole and persistent trophoblastic disease (PTD). Predicting PTD after molar pregnancy might be beneficial since prophylactic chemotherapy reduces the incidence of PTD.
A retrospective study based on blood specimens collected in the Dutch Registry for Hydatidiform Moles. A group of 165 patients with complete moles (of which 43 had PTD) and 39 patients with partial moles (of which 7 had PTD) were compared with 27 pregnant women with uneventful pregnancy.
Serum samples from patients with hydatidiform mole with or without PTD were assayed using specific (radio) immunoassays for free alpha-subunit (hCGalpha), free beta-subunit (hCGbeta) and 'total' hCG (hCG + hCGbeta). In addition, we calculated the ratios hCGalpha/hCG + hCGbeta, hCGbeta/hCG + hCGbeta, and hCGalpha/hCGbeta. Specificity and sensitivity were calculated and paired in receiver-operating characteristic (ROC) curve analysis, resulting in areas under the curves (AUCs).
hCGbeta, hCGbeta/hCG + hCGbeta and hCGalpha/hCGbeta show AUCs ranging between 0.922 and 0.999 and, therefore, are excellent diagnostic tests to distinguish complete and partial moles from normal pregnancy. To distinguish partial from complete moles the analytes hCGbeta, hCG + hCGbeta and the ratio hCGalpha/hCGbeta have AUCs between 0.7 and 0.8. Although hCGalpha, hCGbeta and hCG + hCGbeta concentrations are significantly elevated in patients who will develop PTD compared with patients with spontaneous regression after evacuation of their moles, in predicting PTD, these analytes and parameters have AUCs <0.7.
Distinction between hydatidiform mole and normal pregnancy is best shown by a single blood specimen with hCGbeta, but hCGbeta/hCG + hCGbeta and hCGalpha/hCGbeta are also excellent diagnostic parameters. To predict PTD, hCGalpha, hCGbeta, hCG + hCGbeta and hCGalpha/hCGbeta are moderately accurate tests, although they are not accurate enough to justify prophylactic chemotherapy treatment for prevention of PTD.
人绒毛膜促性腺激素(hCG)广泛应用于葡萄胎和持续性滋养细胞疾病(PTD)的管理。预测葡萄胎妊娠后的PTD可能有益,因为预防性化疗可降低PTD的发生率。
一项基于荷兰葡萄胎登记处收集的血液标本的回顾性研究。将一组165例完全性葡萄胎患者(其中43例发生PTD)和39例部分性葡萄胎患者(其中7例发生PTD)与27例妊娠过程顺利的孕妇进行比较。
使用针对游离α亚基(hCGα)、游离β亚基(hCGβ)和“总”hCG(hCG + hCGβ)的特异性(放射)免疫测定法检测有或无PTD的葡萄胎患者的血清样本。此外,我们计算了hCGα/hCG + hCGβ、hCGβ/hCG + hCGβ和hCGα/hCGβ的比值。计算特异性和敏感性,并在受试者操作特征(ROC)曲线分析中进行配对,得出曲线下面积(AUC)。
hCGβ、hCGβ/hCG + hCGβ和hCGα/hCGβ的AUC在0.922至0.999之间,因此是区分完全性和部分性葡萄胎与正常妊娠的优秀诊断试验。为了区分部分性和完全性葡萄胎,分析物hCGβ、hCG + hCGβ以及hCGα/hCGβ的AUC在0.7至0.8之间。尽管与葡萄胎排空后自然消退的患者相比,将发生PTD的患者的hCGα、hCGβ和hCG + hCGβ浓度显著升高,但在预测PTD方面,这些分析物和参数的AUC<0.7。
通过检测单一血液标本中的hCGβ最能区分葡萄胎与正常妊娠,但hCGβ/hCG + hCGβ和hCGα/hCGβ也是优秀的诊断参数。在预测PTD方面,hCGα、hCGβ、hCG + hCGβ和hCGα/hCGβ是中等准确的检测方法,尽管它们的准确性不足以证明预防性化疗可用于预防PTD。